Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

NowPatient vs Vea Health

NowPatient
Graded #222

Higher grade

vs+10.5
Vea Health
Graded #451

Lower grade

The verdict

NowPatient takes it — 65.5/100 to 55/100.

NowPatient grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NowPatient is a US-UK telehealth platform offering brand-name GLP-1 weight management access including Mounjaro, Wegovy (injection and oral tablet), and Saxenda.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueVea Health +10
35
45
Dose & formulationNowPatient +42
93
51
Clinical oversightNowPatient +20
86
66
Labs & monitoringNowPatient +2
54
52
FulfillmentNowPatient +2
70
68
Contract termsEven
55
55
NowPatient · left barVea Health · right bar

The numbers

MetricNowPatientVea Health
WeighScore65.5/10055/100
GradeCC
Scorecard rank#222#451
Semaglutide$1,349/mo (brand Wegovy)Not disclosed
Tirzepatide$1,069/mo (brand Mounjaro, promotional rate)Not disclosed
CoverageCoverage not publishedAll 50 states
Brand-name accessYesCompounded only
Oral / sublingualYesYes
NowPatient

Graded #222 · C

Strengths

  • Free telehealth consultation — you only pay for the medication
  • Brand-name Mounjaro, Wegovy injection, Wegovy oral tablet, and Saxenda all available
  • One of the few platforms offering Wegovy in both injection and oral pill form
  • No compounded options — every drug is FDA-approved brand-name

Where it loses points

  • Cash-pay pricing tracks full brand list price (~$1,000–$1,350/mo)
  • No compounded semaglutide or tirzepatide (usually the cheaper route)
  • State availability determined during intake, not shown upfront
  • Does not offer Foundayo (orforglipron)
Vea Health

Graded #451 · C

Strengths

  • Publishes the FDA compounded-medication disclaimer
  • Oral and injection protocols for both semaglutide and tirzepatide
  • Claims 50-state coverage via a clinician network
  • Clearly differentiated positioning (longevity, men's health, performance)

Where it loses points

  • Pricing not shown until after sign-up
  • Pharmacy partner not named (only 'U.S.-based pharmacy')
  • LegitScript certification status not visible
  • No named medical director
  • 503A vs 503B designation not specified

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard